We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

4 hedge funds and large institutions have $49K invested in Oasmia Pharmaceutical AB in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

33% less funds holding

Funds holding: 6 → 4 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

78% less capital invested

Capital invested by funds: $226K → $49K (-$177K)

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$24.2K
2
UBS Group
UBS Group
Switzerland
+$700

Top Sellers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
-$179K
2
SM
Sabby Management
Florida
-$17K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$12K
4
Citadel Advisors
Citadel Advisors
Florida
-$2.3K

OASM Hedge Fund Activity: Q1 2018 in Review

4 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q1 2018, worth a combined $49K — down 78% from $226K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of OASM and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $24.2K. The largest seller was Sio Capital Management, exiting entirely with an estimated $179K sold.

  • 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q1 2018, down from 6 in Q4 2017.
  • Funds reported $49K of Oasmia Pharmaceutical AB stock for Q1 2018, down 78% quarter-over-quarter.
  • 1 fund opened new Oasmia Pharmaceutical AB positions in Q1 2018 and 3 closed out, a net change of -2 holders.
  • The largest Oasmia Pharmaceutical AB buyer in Q1 2018 was Susquehanna International Group, an estimated $24.2K added.
  • The largest Oasmia Pharmaceutical AB seller in Q1 2018 was Sio Capital Management, an estimated $179K sold.

Based on aggregated 13F filings for Q1 2018.